Lupin Ltd has cleared inspection of USFDA without any critical observation of Goa manufacturing plant during an inspection in March 2016.
The development comes as a major relief to the company, India’s third largest pharmaceutical firm, as its Goa unit accounts for about 30-40% of its sales in the US. The facility manufactures a range of finished products, including oral solids and injectables. The US is the biggest market for the company, accounting for 43% of the total sales of Rs13,702 crore in 2015-16.
Leave a Reply